![Loading...](https://link.springer.com/static/c4a417b97a76cc2980e3c25e2271af3129e08bbe/images/pdf-preview/spacer.gif)
-
Article
Open AccessA decade of submersible observations revealed temporal trends in elasmobranchs in a remote island of the Eastern Tropical Pacific Ocean
No-take marine protected areas (MPAs) can mitigate the effects of overfishing, climate change and habitat degradation, which are leading causes of an unprecedented global biodiversity crisis. However, assessin...
-
Article
Are there new relevant therapeutic endpoints in the modern era of the BCR::ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia?
-
Article
Open AccessDose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials
Ponatinib, the only approved all known-BCR::ABL1 inhibitor, is a third-generation tyrosine-kinase inhibitor (TKI) designed to inhibit BCR::ABL1 with or without any single resistance mutation, including T315I, ...
-
Article
Open AccessPredictive models for health outcomes due to SARS-CoV-2, including the effect of vaccination: a systematic review
The interaction between modelers and policymakers is becoming more common due to the increase in computing speed seen in recent decades. The recent pandemic caused by the SARS-CoV-2 virus was no exception. Thu...
-
Article
Open AccessA phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents
Pevonedistat is a first-in-class, small molecular inhibitor of NEDD8-activating enzyme that has clinical activity in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Preclinical data suggest s...
-
Article
Cardiovascular Toxicities Associated with Tyrosine Kinase Inhibitors
To provide a detailed overview of cardiovascular adverse events associated with the use of tyrosine kinase inhibitors across different tumor types.
-
Article
Open AccessUnderstanding geographic and racial/ethnic disparities in mortality from four major cancers in the state of Georgia: a spatial epidemiologic analysis, 1999–2019
We examined geographic and racial variation in cancer mortality within the state of Georgia, and investigated the correlation between the observed spatial differences and county-level characteristics. We analy...
-
Article
Open AccessCorrection: Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee
-
Article
Open AccessRetrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee
The phase 2 PACE (Ponatinib Ph+ ALL and CML Evaluation) trial of ponatinib showed robust long-term benefit in relapsed Philadelphia chromosome-positive (Ph+) leukemia; arterial occlusive events (AOEs) occurred...
-
Article
The Care of the Leukemic Patients in Times of SARS-CoV-2
The spread of the novel coronavirus SARS-CoV-2 and its associated disease, coronavirus disease of 2019 (COVID-19), has significantly derailed cancer care. Patients with leukemia are more likely to have severe ...
-
Article
Lesions in octocorals of the Costa Rican Caribbean During The 2015–2016 El Niño
Emerging infectious diseases affecting marine ecosystems are increasing worldwide. Nevertheless, there are very few histopathological analyses describing the tissue damage associated with a specific disease. T...
-
Article
Review of New-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia
In this review, we analyzed the available data from clinical trials with new tyrosine kinase inhibitors (TKIs) under development and how to consider chronic myeloid leukemia (CML) patients who had either resis...
-
Article
High-throughput proteomic profiling reveals mechanisms of action of AMG925, a dual FLT3-CDK4/6 kinase inhibitor targeting AML and AML stem/progenitor cells
FLT3 mutations, which are found in a third of patients with acute myeloid leukemia (AML), are associated with poor prognosis. Responses to currently available FLT3 inhibitors in AML patients are typically transie...
-
Article
Open AccessAuthor Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics
-
Article
Open AccessConcentration–QTc analysis of quizartinib in patients with relapsed/refractory acute myeloid leukemia
This analysis evaluated the relationship between concentrations of quizartinib and its active metabolite AC886 and QT interval corrected using Fridericia’s formula (QTcF) in patients with relapsed/refractory a...
-
Article
Open AccessThird-line therapy for chronic myeloid leukemia: current status and future directions
Chronic myeloid leukemia (CML) is driven by the BCR-ABL1 fusion protein, formed by a translocation between chromosomes 9 and 22 that creates the Philadelphia chromosome. The BCR-ABL1 fusion protein is an optim...
-
Article
Open AccessNivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study
-
Article
Open AccessDecapod crustaceans associated with macroinvertebrates in Pacific Costa Rica
Decapod crustaceans are a diverse group that exploits various types of habitats in Costa Rica, where they represent 8.1% of the marine diversity of the country. This group includes families containing species ...
-
Article
The effect of coral reef degradation on the trophic structure of reef fishes from Bahía Culebra, North Pacific coast of Costa Rica
Fishes play numerous key ecological roles that are critical for maintaining the structure and function of coral reefs. Natural and anthropogenic disturbances can produce structural changes in coral reef habita...
-
Article
Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia
Polo-like kinase 1 (PLK1) regulates mitotic checkpoints and cell division. PLK1 overexpression is reported in numerous cancers, including acute myeloid leukemia (AML), and is associated with poor prognosis. Vo...